

RTW BIOTECH OPPORTUNITIES LTD

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

The Company announces that Nicola Blackwood, non-executive director, purchased an aggregate of 23,373 shares in the fourth quarter of 2025. Due to an oversight these purchases were not notified to the Company and therefore not disclosed publicly. As soon as this oversight was identified the situation was rectified immediately Details of the purchases are set out below.

1	Details of the person discharging managerial responsibilities / person closely associated							
a)	Name	Nicola Blackwood						
2	Reason for the notification							
a)	Position/status	Director						
b)	Initial notification /Amendment	Initial notification						
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor							
a)	Name	RTW Biotech Opportunities Ltd						
b)	LEI	549300Q7EXQQH6KF7Z84						
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted							
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of no par value GG00BKTRRM22						
b)	Nature of the transaction	Purchase of Shares						
c)	Price(s) and volume(s)	<table border="1"><thead><tr><th>Price(s)</th><th>Volume(s)</th></tr></thead><tbody><tr><td>1.5585</td><td>16,493</td></tr><tr><td>2.18844</td><td>6,880</td></tr></tbody></table>	Price(s)	Volume(s)	1.5585	16,493	2.18844	6,880
Price(s)	Volume(s)							
1.5585	16,493							
2.18844	6,880							
d)	Aggregated information - Aggregated volume - Price	23,373 1.7439						
e)	Date of the transaction	6 October 2025 and 23 December 2025						
f)	Place of the transaction	London Stock Exchange						

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how

RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHAKBBPCBKKKDB